ESMO 2024

Gastrointestinal Cancer

Neoadjuvant chemoradiation does not improve surgical outcomes or survival in pancreatic cancer

Presented By

Dr Aurélien Lambert, Lorraine Cancer Institute, France

Trial

Phase 2, PANDAS/PRODIGE 44

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:18

Adding lenvatinib plus pembrolizumab to TACE improves PFS in intermediate-stage HCC

Presented By

Prof. Josep Llovet, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, LEAP-012

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:16

Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time

Presented By

Dr Adam Yopp, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, IMbrave050

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:13

Pre-operative chemoradiation does not improve survival in resectable gastric cancer

Presented By

Prof. Trevor Leong, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, TOPGEAR

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:10

Final results of the IKF-AIO-Moonlight trial

Presented By

Dr Sylvie Lorenzen, Rechts der Isar Hospital, Germany

Trial

Phase 2, IKF-AIO-Moonlight

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:08

Gastrointestinal: Colorectal Cancer

Retifanlimab boosts survival in patients with anal cancer

Presented By

Dr Sheela Rao, Royal Marsden, UK

Trial

Phase 3, POD1UM-303/InterAACT 2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:04

NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer

Presented By

Dr Myriam Chalabi, Netherlands Cancer Institute, the Netherlands; Dr Peter de Gooyer, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:00

Organ-preserving regimens in rectal cancer

Presented By

Dr Alessio Amatu, Niguarda Cancer Center, Italy; Dr Syrine Ben Dhia, Antoine Lacassagne Center, France

Trial

NO-CUT, OPERA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:57

No benefit of high-dose vitamin D3 supplementation in mCRC

Presented By

Dr Kimmie Ng, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, SOLARIS

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:51

More highlights in Colorectal Cancer

Trial

POCHI, LEANOX

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:48

Breast Cancer

Trastuzumab deruxtecan also effective in patients with brain metastases

Presented By

Dr Nancy Lin, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DESTINY-Breast12

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:37

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:35

Local HER2 IHC0 is often HER2-low or -ultralow

Presented By

Prof. Giuseppe Viale, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:32

First-line capivasertib improves PFS but not OS in metastatic TNBC

Presented By

Prof. Heather McArthur, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, CAPItello-290

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:27

Breastfeeding does not increase the risk of breast cancer recurrence

Presented By

Dr Fedro Peccatori, European Institute of Oncology, Italy; Dr Eva Blondeaux, University of Genova, Italy

Trial

POSITIVE, BRCA BCY Collaboration

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:23

More highlights in Breast Cancer

Trial

HERA, NATALEE, KEYNOTE-522, HypoG-01

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:20

Lung Cancer

Melanoma

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Genitourinary Cancer

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:52

Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer

Presented By

Prof. Thomas Powles, University of London; Barts Cancer Center, UK

Trial

Phase 3, NIAGARA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:49

Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection

Presented By

Prof. Hiroshi Kitamura, University of Toyama, Japan

Trial

Phase 3, JCOG1019

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:47

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:44

More highlights in Renal Cell Carcinoma

Trial

LITESPARK-005, SUNNIFORECAST

Type

Peer-reviewed article

4 November 2024 11:42

Genitourinary: Prostate Cancer

Gynaecological Cancer